Ryo Miyata1, Masatsugu Hamaji2, Mitsugu Omasa3, So Miyahara4, Akihiro Aoyama5, Yutaka Takahashi5, Ryota Sumitomo6, Cheng-Long Huang6, Kyoko Hijiya7, Tatsuo Nakagawa8, Yuhei Yokoyama1, Kenzo Kawakami9, Makoto Sonobe10, Masaki Ikeda1, Takuji Fujinaga11, Michiharu Suga12, Shinya Hirota13, Fumitsugu Kojima13, Toru Bando13, Mamoru Takahashi14, Yasuji Terada14, Tsuyoshi Shoji15, Hiromichi Katakura15, Yusuke Muranishi16, Ryo Miyahara16, Hiroshi Date1. 1. Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. 2. Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. mhamaji@kuhp.kyoto-u.ac.jp. 3. Department of Thoracic Surgery, Nishi-Kobe Medical Center, 5-7-1 Koujidai, Nishi-ku, Kobe, 651-2273, Japan. 4. Department of Thoracic Surgery, Fukuoka University Hospital, 7-45-1 Nanakuma, Jyounan-ku, Fukuoka, 814-0180, Japan. 5. Department of Thoracic Surgery, Kobe City Medical Centre General Hospital, 2-1-1 Minatojima-minamicho, Chuo-ku, Kobe, 650-0047, Japan. 6. Department of Thoracic Surgery, Kitano Hospital, The Tazuke Kofukai Medical Institute, 2-4-20 Ougimachi, Osaka, 530-8480, Japan. 7. Department of Thoracic Surgery, Shizuoka Municipal Hospital, 10-93 Outemachi, Aoi-ku, Shizuoka, 420-8630, Japan. 8. Department of Thoracic Surgery, Tenri Hospital, 200 Mishimacho, Tenri, Nara, 632-8552, Japan. 9. Department of Thoracic Surgery, Shiga Medical Center for Adults, 5-4-30 Moriyama, Moriyama, Shiga, 524-0022, Japan. 10. Department of Thoracic Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-8555, Japan. 11. Department of Thoracic Surgery, Nagara Medical Center, 1300-7 Nagara, Gifu, 502-8558, Japan. 12. Department of Thoracic Surgery, Takatsuki Red Cross Hospital, 1-1-1 Abumo, Takatsuki, Osaka, 569-1045, Japan. 13. Department of Thoracic Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. 14. Department of Thoracic Surgery, Kyoto-Katsura Hospital, 17 Yamadahirao-cho, Nishigyo-ku, Kyoto, 615-8256, Japan. 15. Department of Thoracic Surgery, Otsu Red Cross Hospital, 1-1-35 Nagara, Otsu, Shiga, 520-8511, Japan. 16. Department of Thoracic Surgery, Kyoto City Hospital, 1-2 Mibuhigashitakada-cho, Nakagyo-ku, Kyoto, 604-8845, Japan.
Abstract
PURPOSE: There are few data available on the outcomes of postoperative recurrent thymic carcinoma (TC) and thymic neuroendocrine carcinoma (TNEC). The aim of this study is to evaluate the treatment and survival in patients with recurrent TC and TNEC after undergoing surgical resection. METHODS: A retrospective chart review was performed using our multicenter database to identify patients with a postoperative recurrence of TC and TNEC from 1995 to 2018. The clinicopathological factors were reviewed and the survival outcomes were analyzed. RESULTS: Sixty patients were identified among 152 patients who underwent resection of TC and TNEC. The median follow-up period from the first recurrence was 14.8 months (range 0-144). The 5-year post-recurrence survival was 23% for the whole cohort. According to a univariable analysis, advanced stage [hazard ratio (HR) 2.81, 95% confidence interval (CI) 1.09-9.54], interval between primary surgery and recurrence (HR 0.97, 95% CI 0.95-0.99), any treatment for recurrence (HR: 0.27, 95% CI 0.13-0.58) and chemotherapy for recurrence (HR: 0.46, 95% CI 0.22-0.95) were significant factors related to post-recurrence survival. CONCLUSIONS: Chemotherapy rather than surgery appears to be the mainstay treatment for managing patients with postoperative recurrent TC and TNEC and it may also be considered in multidisciplinary management. Further studies with a larger sample size are required to confirm our findings.
PURPOSE: There are few data available on the outcomes of postoperative recurrent thymic carcinoma (TC) and thymic neuroendocrine carcinoma (TNEC). The aim of this study is to evaluate the treatment and survival in patients with recurrent TC and TNEC after undergoing surgical resection. METHODS: A retrospective chart review was performed using our multicenter database to identify patients with a postoperative recurrence of TC and TNEC from 1995 to 2018. The clinicopathological factors were reviewed and the survival outcomes were analyzed. RESULTS: Sixty patients were identified among 152 patients who underwent resection of TC and TNEC. The median follow-up period from the first recurrence was 14.8 months (range 0-144). The 5-year post-recurrence survival was 23% for the whole cohort. According to a univariable analysis, advanced stage [hazard ratio (HR) 2.81, 95% confidence interval (CI) 1.09-9.54], interval between primary surgery and recurrence (HR 0.97, 95% CI 0.95-0.99), any treatment for recurrence (HR: 0.27, 95% CI 0.13-0.58) and chemotherapy for recurrence (HR: 0.46, 95% CI 0.22-0.95) were significant factors related to post-recurrence survival. CONCLUSIONS: Chemotherapy rather than surgery appears to be the mainstay treatment for managing patients with postoperative recurrent TC and TNEC and it may also be considered in multidisciplinary management. Further studies with a larger sample size are required to confirm our findings.
Authors: S S Lee; W Y Park; J G Chi; J W Seo; J I Kim; C W Kim; S H Park; S K Khang; K J Cho; J S Seo; J J Jang Journal: Virchows Arch Date: 1998-01 Impact factor: 4.064